l****z
发帖数: 29846 | 1 U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal
(Reuters) - U.S. drugmaker AbbVie Inc bought Dublin-based Shire Plc on
Friday in a 32 billion pound ($54.7 billion) deal that will allow it to
slash its tax bill by relocating to Britain.
The London-listed company, which makes expensive medicines to treat rare
diseases, fought off four earlier bids from AbbVie until the U.S. firm
raised its price to 52.48 pounds per share - made up of 24.44 pounds in cash
and 0.8960 new AbbV... 阅读全帖 |
|
O****N
发帖数: 1458 | 2 Express Scripts to cover AbbVie hepatitis C drug, drops Gilead treatment
Reuters
7 hours ago
By Caroline Humer
Dec 22 (Reuters) - The nation's largest pharmacy benefit manager has
lined up a cheaper price from AbbVie Inc on its newly approved hepatitis C
treatment and, in most cases, will no longer cover Gilead Sciences Inc
treatments, Express Scripts said on Monday.
Express Scripts has opposed the $84,000 pricetag of Gilead Sciences'
Sovaldi treatment since it was approved a year ago, saying th... 阅读全帖 |
|
p*******r
发帖数: 83 | 3 U.S. FDA approves AbbVie all-oral hepatitis C treatment
Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's all-
oral treatment for hepatitis C, providing the first competition for Gilead
Sciences huge selling and expensive medicine for the liver-destroying virus.
The AbbVie regimen consists of four different anti-viral drugs to be taken
as three pills in the morning and one in the evening. The U.S. Food and Drug
Administration approved the regimen, which will be sold under the... 阅读全帖 |
|
d******8
发帖数: 1972 | 4 Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's all-
oral treatment for hepatitis C, providing the first competition for Gilead
Sciences huge selling and expensive medicine for the liver-destroying virus.
The AbbVie regimen consists of four different anti-viral drugs to be taken
as three pills in the morning and one in the evening. The U.S. Food and Drug
Administration approved the regimen, which will be sold under the brand
name Viekira Pak, for patients with genotype 1 fo... 阅读全帖 |
|
l**y
发帖数: 130 | 5 【 以下文字转载自 Chicago 讨论区 】
发信人: liny (liny), 信区: Chicago
标 题: ABBVIE Position求内推
发信站: BBS 未名空间站 (Wed Feb 19 22:01:35 2014, 美东)
看上一个AbbVie的position, 很MATCH.希望能找个版上在AbbVie的人内推一下，增加下
拿到
interview的机会。多谢多谢 |
|
h****e
发帖数: 374 | 6 批是批了，但也没见怎么涨啊
：U.S. FDA approves AbbVie all-oral hepatitis C treatment
：Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's
all-
：oral treatment for hepatitis C, providing the first competition for Gilead
：Sciences huge selling and expensive medicine for the liver-destroying
virus.
：
：The AbbVie regimen consists of four different anti-viral drugs to be taken
：as three pills in the morning and one in the evening. The U.S. Food and
Drug Administration approved the regimen, which... 阅读全帖 |
|
B******y
发帖数: 9065 | 7 哦，难怪我看到几乎所有的Pipeline都从Abbott转到Abbvie去了，如果是整个Pharma部
门都转的话。不过Abbott的Medical Device很Profitable么，貌似还比不上Pharma，这
样分出去其实划不来呀。还有，现在Abbott和Abbvie到底谁更大一些？Abbvie到底有没
有前景，值得一试么？ |
|
n********r
发帖数: 195 | 8 目前有个offer，给的package比较generous。abbvie邀请onsite，想打听一下abbvie的
senior scientist II （level 18）or III （level 19）的package的大概的range。
如果跟目前的offer差的比较多，就考虑把abbvie的onsite cancel了。（不方便直接回
帖的话，请回站内邮箱，谢谢）
主要glassdoor上给的数字很不靠谱，senior II报了3万股票，3万cash bonus，3万
profit sharing。。。 |
|
q****e
发帖数: 3660 | 9 mm刚上班啊。恭喜找到abbvie
：找人拼车从Vernon Hills到AbbVie（今年年初刚从Abbott分出来成立的新公司）上班。
：会负担油费等相关费用，有兴趣的朋友请站内联系。
：谢谢！！
…… |
|
l**y
发帖数: 130 | 10 看上一个AbbVie的position, 希望能找个版上在AbbVie的人内推一下，增加下拿到
interview的机会。多谢多谢 |
|
B******y
发帖数: 9065 | 11 猎头给我发了一个Abbvie Opening，开始还以为是个小公司，后来才知道是从Abbott分
出来的，但貌似Abbvie比现在的Abbott更继承了老传统一些。这个分家为什么呀？有什
么内幕么？它家的工作值得申请一试么？ |
|
m*********3
发帖数: 1425 | 12 Worcester is not safe compare to Boston and abbvie pipeline is just so so.
If you can find a big pharma in Boston, don't go to abbvie. I don't know the
package of senior scientist II or III, but package for senior scientist I
is not very competitive. |
|
s*****5
发帖数: 52 | 13 接到Abbvie电面邮件，向版上各位有电面经验的前辈请教。
电面需要具体准备哪些呢？HR是不是不会问太多technique based的问题？
十分感谢。
公司是Abbvie-North Chicago, R&D. |
|
m****m
发帖数: 395 | 14 请问有abbvie的内推可以帮忙递简历的吗？不胜感激！ |
|
d******8
发帖数: 1972 | 15 U.S. FDA approves AbbVie all-oral hepatitis C treatment |
|
d******8
发帖数: 1972 | 16 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm42
The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir
, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to
treat patients with chronic hepatitis C virus (HCV) genotype 1 infection,
including those with a type of advanced liver disease called cirrhosis.
Hepatitis C is a viral disease that causes inflammation of the liver that
can lead to reduced liver function, liver failure or liver canc... 阅读全帖 |
|
|
e*********s
发帖数: 1440 | 18 找人拼车从Vernon Hills到AbbVie（今年年初刚从Abbott分出来成立的新公司）上班。
会负担油费等相关费用，有兴趣的朋友请站内联系。
谢谢！！ |
|
|
|
K******c
发帖数: 619 | 21 看pipeline，其实也就一个humira吧，虽然这一个药顶其他药厂几个药了。
所以abbvie现在意识到humira要过期的危机感，开始扩张pipeline了，所以我说他正在
发展中。
虽然是小药厂，但是等pipeline丰满一些了，就马上跻身大药厂行列了 |
|
B***v
发帖数: 113 | 22 Roche, 47 billion
Biogen, 10 billion
NIH, 31 billion
Abbvie, 23 billion
和这些pharma的年revenue比，NIH的研究经费是不是太少了 |
|
x***2
发帖数: 946 | 23 abbvie net income is 5 billion. and the money they devote into r&d is 20%,
say 1 billion. much less than nih. |
|
B***v
发帖数: 113 | 24 你这个对吗？R&D应该是revenue的20%吧？net income是已经减去所有费用（包括R&D）
的净省吧
所以abbvie的R&D大约4-5 billion |
|
j*e
发帖数: 392 | 25 abbvie就是abt的pharma部门独立吧 拳头产品humira受到严重挑战 只好独立出来免得
影响medical device分部 |
|
b******e
发帖数: 3348 | 26 裁人，妥妥的，abbvie要的不过是一个address. |
|
C******y
发帖数: 1997 | 27 应该还好把
主要是减税没错，不过shire做rare disease和abbvie没太多overlap可裁啊 |
|
l**y
发帖数: 130 | 28 【 以下文字转载自 Chicago 讨论区 】
发信人: liny (liny), 信区: Chicago
标 题: 请问版上有在Abbvie工作的吗, 想求助问一个组的情况
发信站: BBS 未名空间站 (Thu Mar 5 18:53:31 2015, 美东)
是在north chicago的那个site. 麻烦站内,多谢 |
|
l**y
发帖数: 130 | 29 【 以下文字转载自 Chicago 讨论区 】
发信人: liny (liny), 信区: Chicago
标 题: 请问版上有在Abbvie工作的吗, 想求助问一个组的情况
发信站: BBS 未名空间站 (Thu Mar 5 18:53:31 2015, 美东)
是在north chicago的那个site. 麻烦站内,多谢 |
|
m*********3
发帖数: 1425 | 30 请问版上有没有Abbvie, chicago, lake county site的,求内推一个职位:
senior scientist I- protein mass spectrometrist position (15000001Q2)
我的背景正好是protein mass spectrometry,请站内联系，包子答谢。谢谢。 |
|
f**v
发帖数: 121 | 31 Abbvie 给的价钱和tittle更高，研究方向和现在一样, 方向比较窄(一般小公司不会做
), 要搬家到Chicago.
illumina给的价钱低，不过不用搬家，研究方向比较宽，应该是做QC一类的。
本来都开始要搬家了，illumina突然跳出来给个offer.求个建议，哪个公司更有前途一
些？ |
|
u*****r
发帖数: 15 | 32 abbvie这公司前景咋样？SAS programming department工作稳定么？待遇咋样？
还请知道的指点一二，谢谢！ |
|
b*********n
发帖数: 2975 | 33 good , big pharma, if you living in chicgo, no brain in
abbvie这公司前景咋样？SAS programming department工作稳定么？待遇咋样？
还请知道的指点一二，谢谢！ |
|
l****z
发帖数: 29846 | 34 http://online.wsj.com/articles/shire-gets-revised-abbvie-takeov
AbbVie Nears $54 Billion Shire Deal
Deal Would Be Latest 'Inversion' Play
By Hester Plumridge
connect
Updated July 14, 2014 2:13 p.m. ET
LONDON—U.S. drug maker AbbVie Inc. ABBV -0.02% is close to clinching
a deal to buy Dublin-based Shire SHPG +2.23% PLC for more than £
31 billion ($53.6 billion), in what would be one of the largest so-called
inversion deals through which U.S. companies are seeking a lower corpo... 阅读全帖 |
|
W***n
发帖数: 11530 | 35 George Soros Just Bought These 3 Stocks: Should You?
By George Budwell
Source: AP
Superinvestors like Warren Buffett and George Soros are closely watched
figures within the investment community for a very good reason: they have a
knack for consistently beating the broader markets. Soros, for instance, has
averaged annual returns in excess of 30% for stretches longer than a decade
during his career. Major stock market indices like the S&P 500, by contrast
, have historically averaged only about 1... 阅读全帖 |
|
d******8
发帖数: 1972 | 36 http://www.thestreet.com/story/12992120/1/abbvies-hep-c-regimen
Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next
By: Adam Feuerstein Follow | 12/19/14 - 04:16 PM EST
inShare
Comment
Link
Stocks in this article: GILDABBVENTA
U.S. regulators approved a new hepatitis C therapy from Abbvie (ABBV) ,
heralding a new era of market competition with Gilead Sciences (GILD) .
The just-approved Abbvie hepatitis C regimen will be sold in the U.S. under
brand name Viekira Pak. The company... 阅读全帖 |
|
y**s
发帖数: 563 | 37 2014年8月27日讯 /生物谷BIOON/ --丙肝治疗领域，吉利德可谓独领风骚，其明星药物
Sovaldi（sofosbuvir）在今年上半年的销售额突破58亿美元，为其带来了滚滚财源。
然而，这一格局即将打破。
近日，百时美施贵宝（BMS）丙肝新药Daklinza（daclatasvir）获欧盟批准，联合其他
药物，用于所有1、2、3、4基因型慢性丙型肝炎（HCV）成人感染者的治疗。Daklinza
是一种强效的泛基因型NS5A复制复合体抑制剂，在临床试验中，当与吉利德明星药
Sovaldi组成一种全口服、无干扰素鸡尾酒疗法（Daklinza+Sovaldi）时，取得了100%
的治愈率，包括伴有晚期肝脏疾病、基因型3 HCV及既往经蛋白酶抑制剂治疗失败的患
者群体。
目前，吉利德也在开发一种基于Sovaldi的丙肝鸡尾酒疗法ledipasvir/Sovaldi（LDV/
SOF），百时美Daklinza/Sovaldi鸡尾酒疗法的获批，对吉利德LDV/SOF鸡尾酒疗法形成
了直接威胁。
Daklinza/Sovaldi是一种每日一次、全口服、治愈率达100%的丙肝鸡尾酒疗法，为... 阅读全帖 |
|
y**s
发帖数: 563 | 38 2014年8月27日讯 /生物谷BIOON/ --丙肝治疗领域，吉利德可谓独领风骚，其明星药物
Sovaldi（sofosbuvir）在今年上半年的销售额突破58亿美元，为其带来了滚滚财源。
然而，这一格局即将打破。
近日，百时美施贵宝（BMS）丙肝新药Daklinza（daclatasvir）获欧盟批准，联合其他
药物，用于所有1、2、3、4基因型慢性丙型肝炎（HCV）成人感染者的治疗。Daklinza
是一种强效的泛基因型NS5A复制复合体抑制剂，在临床试验中，当与吉利德明星药
Sovaldi组成一种全口服、无干扰素鸡尾酒疗法（Daklinza+Sovaldi）时，取得了100%
的治愈率，包括伴有晚期肝脏疾病、基因型3 HCV及既往经蛋白酶抑制剂治疗失败的患
者群体。
目前，吉利德也在开发一种基于Sovaldi的丙肝鸡尾酒疗法ledipasvir/Sovaldi（LDV/
SOF），百时美Daklinza/Sovaldi鸡尾酒疗法的获批，对吉利德LDV/SOF鸡尾酒疗法形成
了直接威胁。
Daklinza/Sovaldi是一种每日一次、全口服、治愈率达100%的丙肝鸡尾酒疗法，为... 阅读全帖 |
|
d******5
发帖数: 4273 | 39 Why Did Gilead Drop Friday? Is It Justified Or Just
An Overreaction?
http://seekingalpha.com/article/2630495-why-did-gilead-drop-fri
Gilead dropped today based on comments during
Abbvie's earnings call that suggested that Abbvie
executives thought their HCV regimen could obtain
an undisclosed market share in 2015.
This is nothing new. Gilead's Harvoni will dominate
the market based on a superior regimen.
Even if Abbvie discounts their regimen, physicians
will still prescribe Harvoni to most pati... 阅读全帖 |
|
d******5
发帖数: 4273 | 40 Reuters
AbbVie to buy cancer drug maker Pharmacyclics in $21 billion deal
AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to
Pharmacyclics stock's closing price on Wednesday on the Nasdaq.
Pharmacyclics stockholders can elect cash, AbbVie stock or a combination,
subject to proration, the company said in a statement. "Imbruvica is not
only complementary to AbbVie's oncology pipeline, it has demonstrated strong
clinical efficacy across a broad range of… |
|
d******5
发帖数: 4273 | 41 Reuters
AbbVie to buy cancer drug maker Pharmacyclics in $21 billion deal
AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to
Pharmacyclics stock's closing price on Wednesday on the Nasdaq.
Pharmacyclics stockholders can elect cash, AbbVie stock or a combination,
subject to proration, the company said in a statement. "Imbruvica is not
only complementary to AbbVie's oncology pipeline, it has demonstrated strong
clinical efficacy across a broad range of… |
|
d******5
发帖数: 4273 | 42 Reuters
AbbVie to buy cancer drug maker Pharmacyclics in $21 billion deal
AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to
Pharmacyclics stock's closing price on Wednesday on the Nasdaq.
Pharmacyclics stockholders can elect cash, AbbVie stock or a combination,
subject to proration, the company said in a statement. "Imbruvica is not
only complementary to AbbVie's oncology pipeline, it has demonstrated strong
clinical efficacy across a broad range of… |
|
d******5
发帖数: 4273 | 43 Reuters
AbbVie to buy cancer drug maker Pharmacyclics in $21 billion deal
AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to
Pharmacyclics stock's closing price on Wednesday on the Nasdaq.
Pharmacyclics stockholders can elect cash, AbbVie stock or a combination,
subject to proration, the company said in a statement. "Imbruvica is not
only complementary to AbbVie's oncology pipeline, it has demonstrated strong
clinical efficacy across a broad range of… |
|
发帖数: 1 | 44 J&J, AbbVie's Imbruvica breaks into larger CLL market with first-line FDA
nod
March 4, 2016
Johnson & Johnson and AbbVie have snagged the indication for standout cancer
med Imbruvica that they've been waiting for.
On Friday, the FDA granted the pair a first-line nod in chronic lymphocytic
leukemia (CLL) based on results of a Phase III trial in which the med cut
the risk of disease progression or death by 84% compared with chemo
treatment chlorambucil.
It's a win for the companies, which already ... 阅读全帖 |
|
d*******3
发帖数: 8598 | 45 虽然生物技术和制药产业的整体前景没有受到经济萧条的影响，但整个行业仍面临重大
的挑战。美国药物研发与制造商协会（PhRMA）指出，企业研发一种新药需要10??15年
的时间、超过12亿美元的投入。但一大批畅销药物的专利即将过期，制药业将面临数百
亿的损失。根据PhRMA的数据，2000年只有49%的处方使用非专利药，但这一比例现在已
达到84%。
最佳雇主如何克服这些重大挑战？首先，是将“科学”定位为组织机构的中心，并把科
学家放在最高领导层。在这些企业中，科学数据是决策和项目方向的驱动，从而将科学
家奉为“掌门人”。
“从整个创新的过程到从一个想法变成临床候选药物的速度，都让在这工作的人兴奋不
已。”位于纽约塔里敦Regeneron制药公司的研发科学高级副总裁Neil Stahl表示。该
生物技术公司已连续两年蝉联《科学》职业“最佳雇主调查”冠军。Stahl指出，公司
在研发用于降低胆固醇的单克隆抗体药物Alirocumab时，从一个想法到临床试验只用了
19个月。这个以创新闻名的公司依靠创新为源动力，打破了药物发现和开发的瓶颈。
“迄今我最喜欢这个公司的是，你进房间时可能只有一丝想... 阅读全帖 |
|
T*****n
发帖数: 274 | 46 不知道这个跟Abbvie丙肝药的市场定向有没有关系。Abbvie早先计划收购Shire并将
headquarter转移到欧洲，以避开美国高昂的（35%）的企业税。尽管最后没有成功，但
体现了欧洲市场在他的蓝图之中。相应的，Abbvie Hep C药明年初会在欧洲获批出售。
而从病毒学分类的角度看，美国的HCV只要是GT1a, 欧洲的更多是GT1b。VIEKIRA PAK看
起来对于1b针对性更强。Harvoni的销售绝大部分是在美国。
比较凌乱，可能都是比较牵强的证据，请在制药业的牛人指点。
who |
|
U******m
发帖数: 423 | 47 最近几年，在一些重要的治疗领域都有非常重要的进展。
以肿瘤的靶向治疗为例，这几年针对Braf V600E的靶点，对黑色素瘤的治疗发生了一个
革命性的变革；在此基础上，目前braf v600E和MEK的抑制剂的合用，可以明显降低耐
药性，下一步mek抑制剂上市应该没有悬念。
对非小细胞肺癌，fda将近6年没批过一个药物，直到fda批准了pfizer的crizotinib，
治疗效果对alk阳性的非小细胞肺癌效果非常显著，近年来ldk378对已经对crizotinib
发生耐药的肿瘤仍然有良好的疗效，ldk378毫无疑问会成为下一个blockbuster。
近年对丙型肝炎病毒的治疗也有革命性的变化。
代谢类疾病，特别是血脂领域，pcsk9的抑制剂已经显示良好的前景。。。
风湿病领域，目前AbbVie的生物药Humira独领风骚，年销售额90亿美元，但是小分子的
jak抑制剂，比如pfizer上市的tofacitinib显示了很好的治疗效果，而且可以口服。
AbbVie承诺支付13.5亿美元预付款及里程金获得Galapagos公司GLPG0634全球许可。该
药是一种JAK1抑制剂用于治疗类... 阅读全帖 |
|
U******m
发帖数: 423 | 48 最近几年，在一些重要的治疗领域都有非常重要的进展。
以肿瘤的靶向治疗为例，这几年针对Braf V600E的靶点，对黑色素瘤的治疗发生了一个
革命性的变革；在此基础上，目前braf v600E和MEK的抑制剂的合用，可以明显降低耐
药性，下一步mek抑制剂上市应该没有悬念。
对非小细胞肺癌，fda将近6年没批过一个药物，直到fda批准了pfizer的crizotinib，
治疗效果对alk阳性的非小细胞肺癌效果非常显著，近年来ldk378对已经对crizotinib
发生耐药的肿瘤仍然有良好的疗效，ldk378毫无疑问会成为下一个blockbuster。
近年对丙型肝炎病毒的治疗也有革命性的变化。
代谢类疾病，特别是血脂领域，pcsk9的抑制剂已经显示良好的前景。。。
风湿病领域，目前AbbVie的生物药Humira独领风骚，年销售额90亿美元，但是小分子的
jak抑制剂，比如pfizer上市的tofacitinib显示了很好的治疗效果，而且可以口服。
AbbVie承诺支付13.5亿美元预付款及里程金获得Galapagos公司GLPG0634全球许可。该
药是一种JAK1抑制剂用于治疗类... 阅读全帖 |
|
O*******f
发帖数: 926 | 49 abbott和abbvie已经是两个不同方向的公司了。
abbvie过去的两年里，似乎没有什么FDA批了的新药，Humira专利过期在望，虽然有并
购但还没有好的pipeline，目前我觉得abbvie步履艰难哈。 |
|
b**********e
发帖数: 2042 | 50 时间：2013年5月4号（星期六）
地点：Baxter Healthcare Corporation, Technology Park 25212 W. IL Rte 120,
Round Lake IL 60073
Conference Program
Plenary lectures by distinguished speakers
▪ Dr. Katharine Qiu, Sr. Director, Medical Products, R&D, Baxter
Healthcare Corporation
▪ Dr. Harold Kung, Professor of Chemical and Biological Engineering,
Northwestern University
▪ Mr. Guy Lewis, Strategic Marketing Director, Honeywell UOP
▪ Dr. Yihong Qiu, Sr. Research Fellow, AbbVie, Inc.
▪ Dr.... 阅读全帖 |
|
